Activity Goals. Activity Goals Case Presentation.

Slides:

Advertisements

Similar presentations

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Advertisements

Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

The Nurse View Key Insights Along the CML Continuum

NOACs for Cancer-Associated Thrombosis:

Improving Survival in Glioblastoma Multiforme

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Current and Future Goals in the Treatment of Relapsed CLL

Treating Transplant-Ineligible Patients With Multiple Myeloma

Goals of Therapy in Relapsed CLL

Updates in Follicular Lymphoma

Novel and Emerging Approaches to Treating CLL

How Can we Improve Outcomes for the Elderly Patient with AML?

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Are We Closer to Personalized Medicine in MS?

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

WHO Clinical Classification of PH Complex Cases in PH.

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

How to Optimize TAVR Outcomes

Recent Advances in the Treatment of Lymphoma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

EHL Technologies in Hemophilia Care

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Minimal Residual Disease in CLL

Personalized Therapy in Relapsed or Refractory CLL

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

How to Select Therapy In Newly Diagnosed CLL

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Personalizing Management in the Care of Patients With Advanced Sarcoma

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

Evaluating BTK Inhibitors in CLL

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

Dr Parag Jasani Consultant Haematologist UCLH

Managing CLL With BTK Inhibitors

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Adherence to Antiplatelet Therapy After an ACS Event

CLL - When to treat, how to treat

Oral Treatment Strategies in CLL

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

AMD Therapy: Where Are We Now and Where Are We Going?

Tailoring Therapy in the Newly Diagnosed Patient With CLL

How to Select Therapy in Relapsed/Refractory CLL

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Binge Eating Disorder.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

MRD Analysis in Chronic Lymphocytic Leukemia

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Risk Stratification in MDS

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

Activity Goals

Case Presentation

Rai Staging

Prognostic Markers

Multivariate Cox Proportional Hazards Model for Survival (n = 1617)

Risk Categories

Diagnostic Tests

MDACC Data: Time to First Treatment

Initial Treatment Choices

PFS in Patients > 70 y: Across Treatment Regimens

Effect of Comorbidity on Outcome of Initial Therapy

Bendamustine  Rituximab

Actuarial PFS With Single-Agent Rituximab

Chlorambucil + Rituximab

Novel Agents

Ibrutinib (PCI-3276)

Idelalisib + Rituximab

Supportive Care

Forthcoming Trial Data

Conclusions About Older Patients With CLL

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)